Complementing broadly neutralizing antibodies and autologous responses to restrict virus escape and durably suppress HIV-1
补充广泛中和抗体和自体反应,以限制病毒逃逸并持久抑制 HIV-1
基本信息
- 批准号:10469169
- 负责人:
- 金额:$ 148.14万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-04-11 至 2027-03-31
- 项目状态:未结题
- 来源:
- 关键词:AIDS preventionAddressAlgorithmsAntibodiesAutologousB-Cell Antigen ReceptorB-LymphocytesBar CodesBinding SitesCellular biologyClinical TrialsCollectionCombined Modality TherapyComplementDataData SetDevelopmentDiseaseEpitopesEvolutionFaceGenetic DriftGoalsGrowthHIVHIV-1In VitroInfectionInterventionLongevityMapsMeasurementMeasuresModelingMolecular VirologyMutationNatural ImmunityOutcomeParticipantPathway interactionsPharmaceutical PreparationsPhenotypePlasmaPolysaccharidesPopulationPreventionPrevention trialResistanceResource DevelopmentRoleSamplingSecureSilicon DioxideTestingVariantViralViremiaVirusVirus ReplicationWorkadaptive immune responseadaptive immunityantagonistclinically relevantcohorthumanized mouseimprovedin vivoin vivo evaluationkinetic modelmultidisciplinaryneutralizing antibodynovelprecision medicinepressurepreventrational designresistance mechanismresponsesimian human immunodeficiency virusviral resistancevirus host interaction
项目摘要
Project Summary/Abstract.
Advances in B cell biology and molecular virology have enabled the discovery, characterization, and commercial
development of several classes of broadly neutralizing antibodies (bnAbs), with applications for prevention,
treatment, and cure of HIV disease are under study. Yet, virus resistance remains the central vulnerability
of effective bnAb use. This application proposes to address the problem of bNAb escape by rationally selecting
combination bNAb therapy that limits virus escape. We propose to apply lessons from the successful
development of combination antiretrovial therapy (cART), whereby bidirectional phenotypic antagonism was
exploited. Our multidisciplinary team has secured plasma virus or virus sequences from recent or ongoing
prevention and treatment studies of VRC01-class CD4 binding site (CD4bs)-targeting monotherapy, as well as
combination therapy with V3 glycan-targeting (Table 1). We will leverage these unique samples to map the in
vivo escape pathways of virus replicating in the presence of sub-suppressive levels of these clinically relevant
bNAbs (Aim 1). Using the evolving escape variants, we will identify putative complementary bNAbs with
maintained or inverse antibody sensitivities from rationally designed panels of candidate bNAbs (Aim 1). We will
then characterize the autologous neutralizing antibody (anAb) response in the treatment cohorts, to determine
the capacity of anAbs to impede virus escape from administered bNAbs (Aim 2). Finally, we will test the most
promising complementary bNAbs to restrict virus escape in vivo in a validated barcoded TF SHIV/NHP model
(Aim 3). Our scientific premise is that in vivo mapping of virus escape from bNAbs, identification of
complementary bNAbs, defining the role of autologous antibodies, and rigorous in vivo testing in an authentic
NHP model will elucidate basic mechanisms of virus resistance to bNAbs and inform more effective use of bNAbs
across the HIV prevention, treatment and cure fields. If accomplished we will (i) have defined the sensitivities of
escaped viruses from clinical trials to alternate bNAbs, (ii) identified bNAbs that cannot mutually escape using
the same pathway, (iii) defined the role of anAbs in bnAb escape and (iv) tested the ability of complementary
bnAbs to improve therapy in an authentic NHP model.
项目概要/摘要。
B细胞生物学和分子病毒学的进展使得能够发现、表征和商业化。
开发几类广泛中和抗体(bnAb),用于预防,
艾滋病的治疗和治愈正在研究中。然而,病毒抵抗力仍然是核心脆弱性
bnAb的有效使用。本申请提出通过合理选择来解决bNAb逃逸的问题
限制病毒逃逸的bNAb联合疗法。我们建议借鉴成功经验,
联合抗逆转录病毒治疗(cART)的发展,其中双向表型拮抗作用,
被剥削我们的多学科团队已经从最近或正在进行的研究中获得了血浆病毒或病毒序列。
VRC 01类CD 4结合位点(CD 4 bs)靶向单药治疗的预防和治疗研究,以及
图1示出了与V3聚糖靶向的联合疗法的实施例(表1)。我们将利用这些独特的样本来绘制
在这些临床相关的亚抑制水平存在下病毒复制的体内逃逸途径
bNAbs(Aim 1)。使用进化的逃逸变体,我们将鉴定推定的互补bNAb,
维持或逆转来自合理设计的候选bNAb组的抗体敏感性(目的1)。我们将
然后表征治疗队列中的自体中和抗体(anAb)应答,以确定
抗体阻止病毒从施用的bNAb逃逸的能力(目的2)。最后,我们将测试最
在经验证的条形码TF SHIV/NHP模型中有希望限制病毒体内逃逸的互补bNAb
(Aim 3)。我们的科学前提是,在体内绘制病毒从bNAb逃逸的图谱,鉴定
互补bNAb,定义自体抗体的作用,以及在真实的
NHP模型将阐明病毒对bNAb的抗性的基本机制,并为更有效地使用bNAb提供信息
在艾滋病预防、治疗和治愈领域。如果完成,我们将(i)确定以下方面的敏感性:
从临床试验中逃逸的病毒替代bNAb,(ii)鉴定出的bNAb不能相互逃逸,
相同的途径,(iii)确定了anAb在bnAb逃逸中的作用,以及(iv)测试了互补的能力。
bnAb以改善真实NHP模型中的治疗。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Katharine June Bar其他文献
Katharine June Bar的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Katharine June Bar', 18)}}的其他基金
Determining the effects of broadly neutralizing antibodies at antiretroviral therapy initiation
确定广泛中和抗体在抗逆转录病毒治疗开始时的作用
- 批准号:
10772448 - 财政年份:2023
- 资助金额:
$ 148.14万 - 项目类别:
Complementing broadly neutralizing antibodies and autologous responses to restrict virus escape and durably suppress HIV-1
补充广泛中和抗体和自体反应,以限制病毒逃逸并持久抑制 HIV-1
- 批准号:
10608215 - 财政年份:2022
- 资助金额:
$ 148.14万 - 项目类别:
Characterizing the viral and host effector mechanisms that govern HIV-1 rebound
表征控制 HIV-1 反弹的病毒和宿主效应机制
- 批准号:
10629260 - 财政年份:2021
- 资助金额:
$ 148.14万 - 项目类别:
Characterizing the viral and host effector mechanisms that govern HIV-1 rebound
表征控制 HIV-1 反弹的病毒和宿主效应机制
- 批准号:
10437036 - 财政年份:2021
- 资助金额:
$ 148.14万 - 项目类别:
Novel macrophage-tropic transmitted/founder SHIV model of CNS persistence to evaluate CRISPR/Cas9 gene editing
用于评估 CRISPR/Cas9 基因编辑的新型巨噬细胞嗜性传播/中枢神经系统持久性 SHIV 模型
- 批准号:
10331568 - 财政年份:2021
- 资助金额:
$ 148.14万 - 项目类别:
Novel macrophage-tropic transmitted/founder SHIV model of CNS persistence to evaluate CRISPR/Cas9 gene editing
用于评估 CRISPR/Cas9 基因编辑的新型巨噬细胞嗜性传播/中枢神经系统持久性 SHIV 模型
- 批准号:
10443900 - 财政年份:2021
- 资助金额:
$ 148.14万 - 项目类别:
Novel macrophage-tropic transmitted/founder SHIV model of CNS persistence to evaluate CRISPR/Cas9 gene editing
用于评估 CRISPR/Cas9 基因编辑的新型巨噬细胞嗜性传播/中枢神经系统持久性 SHIV 模型
- 批准号:
10606618 - 财政年份:2021
- 资助金额:
$ 148.14万 - 项目类别:
Characterizing the viral and host effector mechanisms that govern HIV-1 rebound
表征控制 HIV-1 反弹的病毒和宿主效应机制
- 批准号:
10332623 - 财政年份:2021
- 资助金额:
$ 148.14万 - 项目类别:
Immunological Strategies to Modulate SIV Rebound Following ART Interruption
ART 中断后调节 SIV 反弹的免疫策略
- 批准号:
10224003 - 财政年份:2017
- 资助金额:
$ 148.14万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 148.14万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 148.14万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 148.14万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 148.14万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 148.14万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 148.14万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 148.14万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 148.14万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 148.14万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 148.14万 - 项目类别:
Research Grant